LKFT Stock — Lakefront Biotherapeutics NV

Lakefront Biotherapeutics NV (LKFT)

Updated October 16, 2026.

LKFT is a Stock. Total return is 307.9% over the past 18.3 years, 442.9 points behind SPY at 750.8%.

Lakefront Biotherapeutics NV is a biotechnology company developing medicines in oncology and immunology, with a pipeline focused on CAR-T cell therapies for blood cancers and immunology treatments for conditions like lupus and dermatomyositis; the company maintains a collaboration with Gilead Sciences. The company does not currently have an established distribution schedule. Lakefront Biotherapeutics appeals primarily to growth-oriented investors seeking exposure to early-stage biotech development rather than income investors.

LKFT performance versus SPY

Price and return data through 2026-10-16.

Total return is 307.9% over the past 18.3 years, 442.9 points behind SPY at 750.8%. Over the past year its total return — price change plus distributions reinvested — is -12.3%. Its deepest 1-year drawdown was 24.7%.

LKFT key facts

Asset type

Stock

Asset class

Equity

Inception date

07/07/2008

Distribution frequency

None

Last close

$29.90 (as of 2026-10-16)

Market cap

$1,957,991,633

Average volume

250892.0

Beta

0.058

Payout ratio

0.0%

P/E ratio

2.82

Forward P/E

344.8276

EPS

$10.60

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

LKFT risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 24.7%.

Who may consider LKFT — and who may not

It is a weaker fit for investors who need monthly cash flow (LKFT does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on LKFT

• All tickers starting with L

Tagged: Healthcare.

Frequently asked questions